Polyarteritis Nodosa Market

Market Overview:

The polyarteritis nodosa market reached a value of USD 39.5 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 77.2 Million by ​2035​, exhibiting a growth rate (CAGR) of 6.30% during 2025-2035.

The polyarteritis nodosa market has been comprehensively analyzed in IMARC's new report titled "Polyarteritis Nodosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Polyarteritis nodosa is a systemic necrotizing vasculitis that primarily affects medium-sized muscle arteries but can infrequently impact small muscular arteries, causing subsequent tissue ischemia. The kidneys, skin, joints, muscles, peripheral nerves, and gastrointestinal (GI) tract are the most often affected organs, however any organ can be. The symptoms of polyarteritis nodosa are mostly determined by the location, severity, and extent of secondary ischemia.Patients usually have systemic symptoms such as fever, fatigue, night sweats, loss of appetite, weight loss, and widespread weakness. In some cases, patients suffering from polyarteritis nodosa might also have skin problems, including skin sores, purplish rashes, or nodules under the skin. The diagnostic evaluation of this condition is based on a comprehensive medical history, laboratory studies, and physical examination. The healthcare professional might also recommend imaging tests, such as computed tomography angiogram (CTA) or magnetic resonance angiogram (MRA), that can help visualize blood vessels and identify changes. In some cases, a biopsy of an affected organ is performed to confirm the diagnosis and rule out other numerous conditions.

The escalating prevalence of autoimmune disorders where the body's immune system mistakenly attacks the blood vessels, causing inflammation and damage, is primarily driving the polyarteritis nodosa market. In addition to this, the inflating utilization of immunosuppressants, such as cyclophosphamide, methotrexate, and azathioprine, to reduce inflammation and suppress the immune system's overactivity is also creating a positive outlook for the market. Moreover, the widespread adoption of aneurysm repair surgery on account of its several advantages, like enhanced circulation to vital organs, delayed ischemia and organ damage, and improved long-term survival, is further bolstering the market growth. Apart from this, the rising usage of sirolimus-coated balloon angioplasty, since it inhibits cell overgrowth and maintains vessel patency, thereby reducing the risk of re-narrowing (restenosis), is acting as another significant growth-inducing factor. Additionally, the emerging popularity of anti- tumor necrosis factor-alpha (TNF)-α agents, like infliximab, adalimumab, and etanercept that target and neutralize the activity of TNF -α, is expected to drive the polyarteritis nodosa market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the polyarteritis nodosa market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for polyarteritis nodosa and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polyarteritis nodosa market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the polyarteritis nodosa market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the polyarteritis nodosa market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current polyarteritis nodosa marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the polyarteritis nodosa market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the polyarteritis nodosa market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the polyarteritis nodosa market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of polyarteritis nodosa across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of polyarteritis nodosa by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of polyarteritis nodosa by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with polyarteritis nodosa across the seven major markets?
• What is the size of the polyarteritis nodosa patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of polyarteritis nodosa?
• What will be the growth rate of patients across the seven major markets?

Polyarteritis Nodosa: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for polyarteritis nodosa drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the polyarteritis nodosa market?
• What are the key regulatory events related to the polyarteritis nodosa market?
• What is the structure of clinical trial landscape by status related to the polyarteritis nodosa market?
• What is the structure of clinical trial landscape by phase related to the polyarteritis nodosa market?
• What is the structure of clinical trial landscape by route of administration related to the polyarteritis nodosa market?